Logo image of ZEAL

Zealand Pharma AS (ZEAL) Stock Fundamental Analysis

NASDAQ:ZEAL - Nasdaq - US98920Y3045 - ADR - Currency: USD

17.59  +0.21 (+1.21%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ZEAL. ZEAL was compared to 571 industry peers in the Biotechnology industry. ZEAL may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ZEAL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ZEAL had negative earnings in the past year.
ZEAL Yearly Net Income VS EBIT VS OCF VS FCFZEAL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 500M -500M -1B

1.2 Ratios

Industry RankSector Rank
ROA -94.74%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZEAL Yearly ROA, ROE, ROICZEAL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 50 -50 -100

1.3 Margins

Industry RankSector Rank
OM -509.42%
PM (TTM) -583.94%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZEAL Yearly Profit, Operating, Gross MarginsZEAL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 500 -500 1K -1K 1.5K

More info and screens

3

2. Health

2.1 Basic Checks

ZEAL does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZEAL has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, ZEAL has a worse debt to assets ratio.
ZEAL Yearly Shares OutstandingZEAL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M
ZEAL Yearly Total Debt VS Total AssetsZEAL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 2.94 indicates that ZEAL is not a great score, but indicates only limited risk for bankruptcy at the moment.
ZEAL has a Debt/Equity ratio of 0.93. This is a neutral value indicating ZEAL is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.93
Debt/FCF N/A
Altman-Z 2.94
ROIC/WACCN/A
WACC5.84%
ZEAL Yearly LT Debt VS Equity VS FCFZEAL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 500M -500M 1B -1B

2.3 Liquidity

A Current Ratio of 3.83 indicates that ZEAL has no problem at all paying its short term obligations.
ZEAL has a Quick Ratio of 3.82. This indicates that ZEAL is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 3.83
Quick Ratio 3.82
ZEAL Yearly Current Assets VS Current LiabilitesZEAL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.09% over the past year.
The Revenue has grown by 25.74% in the past year. This is a very strong growth!
Measured over the past years, ZEAL shows a small growth in Revenue. The Revenue has been growing by 4.85% on average per year.
EPS 1Y (TTM)3.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60.7%
Revenue 1Y (TTM)25.74%
Revenue growth 3Y97.5%
Revenue growth 5Y4.85%
Sales Q2Q%-22.36%

3.2 Future

Based on estimates for the next years, ZEAL will show a small growth in Earnings Per Share. The EPS will grow by 1.84% on average per year.
The Revenue is expected to grow by 39.94% on average over the next years. This is a very strong growth
EPS Next Y-5.24%
EPS Next 2Y10.12%
EPS Next 3Y12.18%
EPS Next 5Y1.84%
Revenue Next Year13.79%
Revenue Next 2Y53.87%
Revenue Next 3Y32.58%
Revenue Next 5Y39.94%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ZEAL Yearly Revenue VS EstimatesZEAL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B
ZEAL Yearly EPS VS EstimatesZEAL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 10 -10 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZEAL. In the last year negative earnings were reported.
Also next year ZEAL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZEAL Price Earnings VS Forward Price EarningsZEAL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -5.79
ZEAL Per share dataZEAL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as ZEAL's earnings are expected to grow with 12.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.12%
EPS Next 3Y12.18%

More info and screens

0

5. Dividend

5.1 Amount

ZEAL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Zealand Pharma AS

NASDAQ:ZEAL (9/29/2022, 8:02:19 PM)

17.59

+0.21 (+1.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2022-08-11/amc
Earnings (Next)11-09 2022-11-09
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap811.25M
Analysts85.71
Price Target28.31 (60.94%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.21
P/FCF N/A
P/OCF N/A
P/B 12.2
P/tB N/A
EV/EBITDA -5.79
EPS(TTM)-3.45
EYN/A
EPS(NY)-2.36
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.58
BVpS1.44
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -94.74%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -509.42%
PM (TTM) -583.94%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.93
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.83
Quick Ratio 3.82
Altman-Z 2.94
F-Score3
WACC5.84%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60.7%
EPS Next Y-5.24%
EPS Next 2Y10.12%
EPS Next 3Y12.18%
EPS Next 5Y1.84%
Revenue 1Y (TTM)25.74%
Revenue growth 3Y97.5%
Revenue growth 5Y4.85%
Sales Q2Q%-22.36%
Revenue Next Year13.79%
Revenue Next 2Y53.87%
Revenue Next 3Y32.58%
Revenue Next 5Y39.94%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A